bioRxiv ScienceSearch

bioRxiv · 10.1101/365403

Integrative data analysis predicts YY1 as a Cis-regulator in the 3D Cell Culture Models of MCF10A at the Stiffness Level of High Mammographic Density

Abstract

Previous studies have shown that in 3D cell culture models of human mammary cells (HMEC) (i) colony organizations are heterogeneous, and (ii) ERBB2 is overexpressed in MCF10A when the stiffness of the microenvironment is increased to that of high mammographic density (MD). The goal of the current study is to identify transcription factors that regulate processes associated with the increased stiffness of the microenvironment. Two HMEC premalignant lines of MCF7 and 184A1 are cultured in 3D, colonies are imaged using confocal microscopy, and colony organizations and heterogeneity are quantified as a function of the stiffness of the microenvironment. In parallel and surrogate assays, colony organizations are profiled by transcriptomics. Transcriptome data are enriched by correlative analysis with the computed morphometric indices, from 3D culture, and a subset of transcriptome data is selected. This subset is then processed with Model-based Analysis of Regulation of Gene Expression (MARGE) and publicly available ChIP-seq data to predict regulatory transcription factors. The integrative analysis indicated that YY1 regulates ERBB2 in the 3D cell culture of MCF10A when the stiffness of the microenvironment is increased to that of high MD. Subsequent experimental validation confirmed that YY1 is only expressed at the high stiffness value of the microenvironment concomitant with the overexpression of ERBB2 in MCF10A. Furthermore, using ERBB2 positive SKBR3 cell line, co-expression of YY1 and ERBB2 is absent, which indicates that YY1 regulates tumorigenicity through multiple pathways.\n\nAuthors summaryMCF10A is a premalignant immortalized human mammary cell that has been isolated from a patient with fibrocystic and lost several barriers toward transformation. In an earlier study, we showed that ERBB2 is upregulated in 3D cultures of MCF10A when the stiffness of the microenvironment is increased to that of high mammographic density. Here, we leverage publicly available ChIP-seq data to predict and validate the cis-regulator of ERBB2. Our integrated experimental and computation protocol provides a pathway for elucidating regulators that can potentially be targeted for intervention.

Explore related subjects

Keep this discovery

BibTeXRIS

Cheng, Q., Khoshdeli, M., Zang, C., Parvin, B.. 2018-07-09. Integrative data analysis predicts YY1 as a Cis-regulator in the 3D Cell Culture Models of MCF10A at the Stiffness Level of High Mammographic Density. https://doi.org/10.1101/365403

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology